financetom
Business
financetom
/
Business
/
Newsletter | Tata Group to be 1st Indian iPhone maker; IT, startup hiring sees drop; startup uses AI for customer service; tech and more
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Newsletter | Tata Group to be 1st Indian iPhone maker; IT, startup hiring sees drop; startup uses AI for customer service; tech and more
Jul 12, 2023 3:23 AM

Here's a rundown of 11 significant news stories to keep you in the know:

Share Market Live

NSE

ideaForge shares have doubled from their IPO price — Should one buy now?

They say a good start is half the job done. ideaForge Technology, India's largest drone manufacturing company has had everything going its way in recent times - The best IPO subscription figures in nearly two years, the best listing in nearly two years and so on.

Shares of ideaForge listed at a 93 percent premium to its IPO price of Rs 672. At the listing day high of Rs 1,344, the stock was exactly double of its IPO price. The stock fell 10 percent on Monday and recovered another 9 percent on Tuesday. Although the stock is currently below its listing price, IPO shareholders are still sitting on substantial profits.

But should a new investor attempt to buy the stock? At elevated prices?

Read here

Tata Group will be first Indian iPhone maker, deal likely to close in August

Tata Group, India’s largest conglomerate, is close to an agreement to acquire an Apple Inc. supplier’s factory as soon as August, marking the first time a local company would move into the assembly of iPhones, according to people familiar with the matter.

A takeover of the Wistron Corp. factory in southern Karnataka state, potentially valued at more than $600 million, would cap about a year of negotiations, said the people, asking not to be named as the matter is private. The facility employs more than 10,000 workers, who assemble the latest iPhone 14 model.

Read here

#TechTalks

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2025 - www.financetom.com All Rights Reserved